Formulation patents no longer eligible for PTE in Australia

The provision of patent term extensions (PTEs) and supplementary protection certificates (SPCs) under law are designed to account for significant delays encountered in obtaining regulatory approval for pharmaceutical products. Australia has previously enjoyed a relatively broad approach to PTEs. However, a recent decision by the Full Federal Court in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ